Imatinib Mesylate in Treating Patients With Recurrent Ewing's Family of Tumors or Desmoplastic Small Round-Cell Tumor
Status:
Completed
Trial end date:
2007-06-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Imatinib mesylate may stop the growth of tumor cells by blocking the enzymes
necessary for tumor cell growth.
PURPOSE: This phase II trial is studying how well imatinib mesylate works in treating
patients with recurrent Ewing's family of tumors or desmoplastic small round-cell tumor.